Theralase Technologies Inc. Share Price
Stocks
TLT
CA88337V1004
Advanced Medical Equipment & Technology
OTC Markets Traded|
Market Closed -
Toronto S.E.
08:01:47 02/11/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 0.1950 CAD | +8.33% |
|
-2.50% | +18.18% |
| 26/10 | Theralase® Technologies Inc. Provides Bladder Cancer Clinical Study Update and Oncology Pipeline Expansion | CI |
| 15/09 | Theralase Technologies Commences GLP Toxicology Analysis of Rutherrin | CI |
| Market Cap | 6.05Cr 4.33Cr 3.87Cr 3.55Cr 3.23Cr 410.21Cr 6.18Cr 42Cr 17Cr 216.52Cr 16Cr 16Cr 683.88Cr | P/E 2026 * |
-19.5x | P/E 2027 * | 9.75x |
|---|---|---|---|---|---|
| Enterprise Value | 6.05Cr 4.33Cr 3.87Cr 3.55Cr 3.23Cr 410.21Cr 6.18Cr 42Cr 17Cr 216.52Cr 16Cr 16Cr 683.88Cr | EV / Sales 2026 * |
77x | EV / Sales 2027 * | 1.79x |
| Free-Float |
79.6% | Yield 2026 * |
-
| Yield 2027 * | - |
Toronto S.E.CAD
| Markets | Quality | ||
|---|---|---|---|
Toronto S.E.
| TLT | Delayed | |
OTC Markets
| TLTFF | Delayed | |
Deutsche Boerse AG
| TTX | Delayed | |
Börse Stuttgart
| TTX | Delayed |
Last Transcript: Theralase Technologies Inc.
| 1 day | +8.33% | ||
| 1 week | -2.50% | ||
| Current month | +8.33% | ||
| 1 month | +11.43% | ||
| 3 months | -31.58% | ||
| 6 months | -36.07% | ||
| Current year | +18.18% |
| 1 week | 0.18 | 0.2 | |
| 1 month | 0.18 | 0.25 | |
| Current year | 0.16 | 0.41 | |
| 1 year | 0.14 | 0.41 | |
| 3 years | 0.14 | 0.41 | |
| 5 years | 0.14 | 0.48 | |
| 10 years | 0.12 | 0.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 29/06/2023 | |
Kristina Hachey
DFI | Director of Finance/CFO | - | 27/06/2019 |
Arkady Mandel
CEO | Chief Executive Officer | - | 15/11/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | - | - | |
Randy Bruder
BRD | Director/Board Member | - | 01/01/2008 |
Kristina Hachey
BRD | Director/Board Member | - | 27/06/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 31/08/26 | Option | Director | 3,360 | 0.0011% | ||
| 27/08/26 | Buy | Chief Executive Officer | 42,000 | 0.0142% | ||
| 24/08/26 | Option | Chief Financial Officer | 29,000 | 0.0098% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +8.33% | -2.50% | -7.14% | 0.00% | 4.33Cr | ||
| -2.06% | -0.33% | +20.31% | +52.52% | 25TCr | ||
| -1.83% | -2.15% | +5.85% | +18.13% | 16TCr | ||
| +1.12% | -3.27% | -18.23% | +57.21% | 15TCr | ||
| +5.57% | -2.76% | -56.00% | -15.61% | 6.42TCr | ||
| +1.19% | +2.62% | -10.64% | -8.42% | 5.41TCr | ||
| +1.36% | +2.98% | +13.11% | +42.32% | 5.38TCr | ||
| -1.90% | -3.51% | +5.43% | +61.66% | 4.97TCr | ||
| -1.65% | -2.26% | +17.51% | +64.63% | 4.85TCr | ||
| -2.85% | -1.41% | +28.58% | +83.18% | 4.42TCr | ||
| Average | +0.73% | -2.41% | -0.12% | +35.56% | 8.79TCr | |
| Weighted average by Cap. | -0.51% | -1.28% | +2.53% | +40.43% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8L 6L 5L 5L 4L 5.33Cr 8L 55.05L 22.19L 2.81Cr 21.11L 20.66L 8.88Cr | 3.39Cr 2.43Cr 2.17Cr 1.99Cr 1.81Cr 229.61Cr 3.46Cr 24Cr 9.57Cr 121.19Cr 9.1Cr 8.91Cr 382.78Cr |
| Net income | -41.24L -29.51L -26.35L -24.18L -22L -28Cr -42.06L -2.89Cr -1.16Cr -15Cr -1.11Cr -1.08Cr -47Cr | 69.01L 49.39L 44.09L 40.46L 36.81L 47Cr 70.39L 4.83Cr 1.95Cr 25Cr 1.85Cr 1.81Cr 78Cr |
| Net Debt | - | - |
Employees
20
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/26/02 | CA$0.1950 | +8.33% | 1,285 |
| 30/26/30 | CA$0.1800 | -10.00% | 1,39,043 |
| 29/26/29 | CA$0.2000 | 0.00% | 23,500 |
| 28/26/28 | CA$0.2000 | 0.00% | 39,890 |
| 27/26/27 | CA$0.2000 | 0.00% | 1,13,762 |
Sell
Buy

Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.1950CAD
Average target price
0.7000CAD
Spread / Average Target
+258.97%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- TLT Stock
Select your edition
All financial news and data tailored to specific country editions

















